Lindsey Shapiro, PhD,  science writer—

Vyvgart (efgartigimod) eased symptoms of generalized myasthenia gravis (gMG) in patients regardless of their disease length, treatment history, or acetylcholine receptor (AChR) antibody status, according to two new analyses from the ADAPT clinical trial and its open-label extension, ADAPT+. These findings serve to reinforce “the efficacy of efgartigimod…

Sanofi is stopping the clinical development of tolebrutinib for treating myasthenia gravis (MG), the company announced in a recent press release. The decision was made after “careful evaluation of the emerging competitive treatment landscape in MG,” according to Sanofi, and will result in discontinuing the Phase…

MuSK-CAART, an investigational cell-based therapy being developed to treat myasthenia gravis (MG) patients with anti-MuSK antibodies, eliminated disease-driving B-cells in a mouse model of the disease, a study showed. The findings, some of which were reported previously at a scientific conference, supported Cabaletta Bio’s request for a…

Treatment with an antibody targeting the interleukin-23 (IL-23) protein reduced symptoms and eased inflammation in mouse models of myasthenia gravis (MG), a study found. Evidence suggested the antibody lowers the activation of T-helper 17 (Th17) cells — a cell family implicated in MG and other autoimmune diseases — in…

Researchers have identified clinical factors that increase the risk of a post-operative myasthenic crisis (POMC) for patients with myasthenia gravis (MG) who have surgery to remove the thymus gland. Among the risk factors listed are more severe MG with respiratory muscle involvement, pre-operative use of a high dose of pyridostigmine…

Shedding of the muscle-specific tyrosine kinase (MuSK) protein from the surface of muscle cells into the bloodstream could be the reason why anti-MuSK antibodies drive myasthenia gravis (MG) in some cases, according to a study. The protein was found in the blood of healthy mice and people, and was…

Analyzing the motor end-plate (MEP) — the specialized muscle region that communicates with a nerve cell — using a muscle biopsy could help diagnose patients with myasthenia gravis (MG) who test negative for common disease-associated antibodies, a small study suggests. Among patients with MG-like symptoms who were negative on…

The National Institutes of Health (NIH) is supporting a pilot project that aims to develop a simple and fast diagnostic lab test for myasthenia gravis (MG). With the one-year, $100,000 NIH award, researchers at the University of California, Davis, will work to develop an assay able to identify disease-causing antibodies…

Treatment with the diabetes medication metformin suppresses the growth of immune T- and B-cell subsets that are implicated in the development of myasthenia gravis (MG), according to a study in a rat model of the neuromuscular disease. Metformin appeared to exert these positive effects by reversing the abnormal levels…

Two investigational UCB treatments for generalized myasthenia gravis (gMG) — zilucoplan and rozanolixizumab — continue to show benefits in gMG patients, according to recently reported findings from Phase 3 trials. Both delivered as subcutaneous (under-the-skin) injections, zilucoplan works by blocking an immune system protein called C5 that…